MedKoo Cat#: 555652 | Name: XPC-6444

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XPC-6444 is a highly potent inhibitors of NaV1.6 with high selectivity over NaV1.1 and NaV1.5. XPC-6444 provided excellent anticonvulsant activity and reduced seizure activity in a dose-dependent manner in an induced seizure model, which utilized SCN8A GOF mice carrying the N1768D mutation identified in a human EIEE13 patient.

Chemical Structure

XPC-6444
XPC-6444
CAS#2230144-21-3

Theoretical Analysis

MedKoo Cat#: 555652

Name: XPC-6444

CAS#: 2230144-21-3

Chemical Formula: C22H25F3N4O2S2

Exact Mass: 498.1371

Molecular Weight: 498.58

Elemental Analysis: C, 53.00; H, 5.05; F, 11.43; N, 11.24; O, 6.42; S, 12.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
XPC-6444; XPC 6444; XPC6444;
IUPAC/Chemical Name
4-((2-((tert-Butyl(methyl)amino)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide
InChi Key
VOJFVKGTRNXOTJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H25F3N4O2S2/c1-22(2,3)29(4)11-14-6-5-7-17(23)16(14)10-26-15-8-18(24)21(19(25)9-15)33(30,31)28-20-12-32-13-27-20/h5-9,12-13,26,28H,10-11H2,1-4H3
SMILES Code
O=S(C1=C(F)C=C(NCC2=C(F)C=CC=C2CN(C(C)(C)C)C)C=C1F)(NC3=CSC=N3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Nonselective antagonists of voltage-gated sodium (NaV) channels have been long used for the treatment of epilepsies. The efficacy of these drugs is thought to be due to the block of sodium channels on excitatory neurons, primarily NaV1.6 and NaV1.2. However, these currently marketed drugs require high drug exposure and suffer from narrow therapeutic indices. Selective inhibition of NaV1.6, while sparing NaV1.1, is anticipated to provide a more effective and better tolerated treatment for epilepsies. In addition, block of NaV1.2 may complement the anticonvulsant activity of NaV1.6 inhibition.

Preparing Stock Solutions

The following data is based on the product molecular weight 498.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective NaV1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy Thilo Focken*Kristen BurfordMichael E. GrimwoodAlla ZenovaJean-Christophe AndrezWei GongMichael WilsonMatt TaronShannon DeckerVerner LofstrandSultan ChowdhuryNoah ShuartSophia LinSamuel J. GoodchildClint YoungMaegan SorianoParisa K. TariMatthew WaldbrookKaren NelkenbrecherRainbow KwanAndrea LindgrenGina de BoerStephanie LeeLuis SojoRobert J. DeVitaCharles J. CohenSteven S. WesolowskiJ. P. Johnson Jr.Christoph M. DehnhardtJames R. Empfield Journal of Medicinal Chemistry, Articles ASAP (As Soon As Publishable)Subscribed Access Publication Date (Web):September 17, 2019